IL6R and congenital rubella syndrome: Furthermore, in light of the unprecedented COVID-19 pandemic where life-threatening infections were observed resulting in CRS, not only tocilizumab but also sarilumab, another antibody directed against IL-6R, have gained importance in the management of CRS in critically ill patients (35–42).